Interpreting cost-effectiveness analysis studies in gynecology
DOI:
https://doi.org/10.18597/rcog.238Keywords:
economic evaluation in healthcare, cost-effectiveness analysisAbstract
Objectives: explaining concepts related to economic evaluation in healthcare by using a critical cost-effectiveness analysis (CEA) study.
Materials and methods: a search was made of the Medline database via PubMed based on a clinical question. A study was selected which approached the matter in hand. The elements which a reader should bear in mind were set out; they were explained by means of examples from already published economic evaluation in healthcare studies regarding gynecology and a critical analysis was made of these aspects in the selected publication.
Results: the following elements must be taken into account for a critical reading of a CEA study: the alternatives for making comparisons, cost determination, effectiveness, the incremental cost-effectiveness ratio and a sensitivity analysis. Understanding these elements will lead to a much deeper evaluation of such studies.
Conclusions: economic evaluation deserves to be considered by healthcare professionals as this leads to efficient decisions being taken when treating patients.
Author Biographies
Johanna Aponte-González
Javier Eslava-Schmalbach
Jorge A. Díaz-Rojas
Hernando Gaitán-Duarte
References
Fuchs VR. The future of health economics. J Health Econ 2000;19:141-57.
Baily MA. Futility, autonomy, and cost in end-of-life care. J Law Med Ethics 2011;39:172-82.
Mooney GH, Drummond MF. Essentials of health economics: part III-developing health care policies. Br Med J (Clin Res Ed) 1982;285:1263-4.
Mooney GH, Drummond MF. Essentials of health economics: Part I-What is economics? Br Med J (Clin Res Ed) 1982;285:949-50.
Catalá-López F. Efficiency-based healthcare. General concepts on economic evaluation of healthcare interventions. Enferm Clin 2009;19:35-42.
Lozano JM. Apreciación crítica de la literatura. En: Ruiz A, Morillo L. Epidemiología clínica. Investigación clínica aplicada, capítulo 31. Bogotá: Editorial Médica Internacional; 2004.
Gray AM. Cost-effectiveness analyses alongside randomised clinical trials. Clin Trials 2006;3:538-42.
Soegaard R, Bünger CE, Christiansen T, Christensen FB. Determinants of cost-effectiveness in lumbar spinal fusion using the net benefit framework: a 2-year follow-up study among 695 patients. Eur Spine J 2007;16:1822-31.
Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, Battegay M; Swiss HIV cohort study. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One 2007;2:e173.
Chan AL, Wang Hy. Pharmacoeconomic assessment of clinical pharmacist interventions for patients with moderate to severe asthma in outpatient clinics: experience in Taiwan. Clin Drug Investig 2004;24:603-9.
Palmer S, Byford S, Raftery J. Economics notes: types of economic evaluation. BMJ 1999;318:1349.
Robinson R. Cost-effectiveness analysis. BMJ 1993;307:793-5.
Robinson R. Cost-utility analysis. BMJ 1993;307:859-62.
Robinson R. Costs and cost-minimisation analysis. BMJ 1993;307:726-8.
Eslava-Schmalbach J, Barón G, Gaitán-Duarte H, Alfonso H, Agudelo C, Sánchez C. Evaluating cost/ equity in the Colombian health system, 1998-2005. Rev Salud Pública 2008;10:3-17.
Robinson R. Economic evaluation and health care. What does it mean? BMJ 1993;307:670-3.
Chocontá-Piraquive LA, Alvis-Guzmán N, De la Hoz-Restrepo F. How protective is cervical cancer screening against cer vical cancer mortality in developing countries? The Colombian case. BMC Health Serv Res 2010;10:270.
Instituto Nacional de Cancerología-Colombia. Todo sobre el cáncer de cuello uterino. Información institucional. Instituto Nacional de Cancerología; 2009. Visitado en 2011 Abr 15. Disponible en : http://www.incancerologia.gov.co.
Instituto Nacional de Cancerología- Colombia. Mortalidad por cáncer primeras causas y sexo. Bogotá: Instituto Nacional de Cancerología; 2004. Visitado 2011 Abr 15. Disponible en: http://www.cancer.gov.co/documentos/794_cancer.pdf.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009;374:301-14.
Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009;40:503-13.
Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1997;277:1552-7.
Sung VW, Washington B, Raker CA. Costs of ambulatory care related to female pelvic floor disorders in the United States. Am J Obstet Gynecol 2010;202:483.e1-4.
Petiti D. Advanced cost-effectiveness analysis. En: Petiti D. Meta-analysis decision analysis and costeffectiveness analysis. Chapter 12. New york: Oxford University Press; 1994.
Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006;98:92-100.
Muennig P. Designing and conducting costeffectiveness analyses. Medicine and Health Care. San Francisco: Jossey-Bass; 2002.
Gaitán- Duarte H, Eslava-Schmalbach J , Rodríguez-Malagón N, Forero-Supelano V, Santofimio-Sierra D, Altahona H. Incidence and preventability of adverse events in patients hospitalised in three Colombian hospitals during 2006. Rev Salud Pública 2008;10:215-26.
Tugwell P, Bennett KJ, Sackett DL, Haynes RB. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis 1985;38:339-51.
Helfert EA. Técnicas de análisis financiero. Barcelona: Editorial Labor; 1973.
Gold MR, Siegel JE, Russell LB, Weinstein MC. Costeffectiveness in Health and Medicine. New york: Oxford University Press; 1996.
Ministerio de la Protección Social, Colciencias, Centro de Estudios e Investigación en Salud de la Fundación Santa Fe de Bogotá, Escuela de Salud Pública de la Universidad de Harvard. Guía metodológica para el desarrollo de guías de atención integral en el sistema general de seguridad social en salud colombiano. Bogotá, Colombia; 2010.
Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health 2011;56:153-62.
Bear R, Schneiderman J. Decision analysis in clinical medicine. Can Med Assoc J 1976;115:833-6.
Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990;10:212-4.
Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmacoeconomics--an aid to better decision-making. J Eur Acad Dermatol Venereol 2005;19:S34-9.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
